Drug Type Fc fusion protein |
Synonyms SG 1827, SG1827 |
Target |
Action modulators, stimulants |
Mechanism CD28 modulators(T-cell-specific surface glycoprotein CD28 modulators), CTLA4 modulators(Cytotoxic T-Lymphocyte-Associated Antigen 4 modulators), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | China | 19 Sep 2023 |